Coherus pulls first interchangeable biosimilar win for Lucentis copycat

Move over, Lucentis. The FDA has approved the first interchangeable biosimilar to Roche’s blockbuster anti-VEGF drug.

Coherus’ Cimerli is expected to hit the market in October after getting the FDA’s thumbs-up in five retinal indications, the company announced on Tuesday. Cimerli isn’t the first biosimilar to rival Roche’s eye drug...

Click to view original post